Comments
Loading...
Genmab Earnings Estimates, EPS & Revenue | NASDAQ:GMAB | Benzinga
Genmab reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
May 8
EPS
$0.310
Quarterly Revenue
$715.00M
Annual Revenue
(as of Mar 31)
(as of Mar 31)
$3.12B
Analyze the earnings history of Genmab using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GMAB | Genmab | $0.31 | — | — | — | $779.51M | — | — | — | 08/07/2025 | Get Alert |
| GMAB | Genmab | $0.29 | $0.23 | $0.31 | 34.78% | $600.43M | $748.58M | $715.00M | -4.49% | 05/08/2025 | Get Alert |
| GMAB | Genmab | $0.36 | $0.28 | $0.85 | 203.57% | $675.05M | $885.31M | $921.56M | 4.09% | 02/12/2025 | Get Alert |
| GMAB | Genmab | $0.47 | $0.35 | $0.29 | -17.14% | $692.70M | $828.46M | $816.01M | -1.50% | 11/06/2024 | Get Alert |
| GMAB | Genmab | $0.30 | $0.33 | $0.31 | -6.06% | $613.49M | $733.18M | $779.51M | 6.32% | 08/08/2024 | Get Alert |
| GMAB | Genmab | $0.05 | $0.14 | $0.29 | 107.14% | $411.34M | $577.46M | $600.43M | 3.98% | 05/02/2024 | Get Alert |
| GMAB | Genmab | $0.12 | $4.02 | $0.36 | -91.04% | $699.51M | $679.55M | $675.05M | -0.66% | 02/14/2024 | Get Alert |
| GMAB | Genmab | $0.53 | — | $0.47 | — | $553.75M | $630.48M | $692.70M | 9.87% | 11/07/2023 | Get Alert |
| GMAB | Genmab | $0.41 | $0.31 | $0.30 | -2.90% | $453.01M | $618.77M | $613.49M | -0.85% | 08/03/2023 | Get Alert |
| GMAB | Genmab | $0.11 | $0.65 | $0.05 | -92.31% | $319.67M | $417.90M | $411.34M | -1.57% | 05/10/2023 | Get Alert |
| GMAB | Genmab | $0.17 | $3.18 | $0.12 | -96.23% | $402.80M | $664.17M | $699.51M | 5.32% | 02/22/2023 | Get Alert |
| GMAB | Genmab | $0.21 | $1.63 | $0.53 | -67.48% | $366.37M | $475.35M | $553.75M | 16.49% | 11/09/2022 | Get Alert |
| GMAB | Genmab | $0.08 | $1.58 | $0.41 | -74.05% | $319.46M | $404.75M | $453.01M | 11.92% | 08/10/2022 | Get Alert |
| GMAB | Genmab | $0.27 | — | $0.11 | — | $256.28M | $319.59M | $319.67M | 0.02% | 05/11/2022 | Get Alert |
| GMAB | Genmab | $0.14 | — | $0.17 | — | $327.45M | — | $402.80M | — | 02/16/2022 | Get Alert |
| GMAB | Genmab | $0.13 | — | $0.21 | — | $270.67M | $319.59M | $366.37M | 14.64% | 11/10/2021 | Get Alert |
| GMAB | Genmab | $0.76 | — | $0.08 | — | $804.57M | — | $319.46M | — | 08/11/2021 | Get Alert |
| GMAB | Genmab | $0.06 | $0.23 | $0.27 | 17.39% | $131.66M | $207.51M | $256.28M | 23.50% | 05/05/2021 | Get Alert |
| GMAB | Genmab | $0.34 | $1.17 | $0.14 | -88.03% | $444.15M | $303.75M | $327.45M | 7.80% | 02/23/2021 | Get Alert |
| GMAB | Genmab | $0.12 | $0.91 | $0.13 | -85.71% | $155.98M | $247.63M | $270.67M | 9.30% | 11/04/2020 | Get Alert |
| GMAB | Genmab | $0.02 | — | $0.76 | — | $115.61M | — | $804.57M | — | 08/12/2020 | Get Alert |
Genmab (GMAB) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q1 | 2025-05-08 | $0.31 | $0.23 | 34.8 % |
| Q4 | 2025-02-12 | $0.85 | $0.28 | 203.6 % |
| Q3 | 2024-11-06 | $0.29 | $0.35 | -17.1 % |
| Q2 | 2024-08-08 | $0.31 | $0.33 | -6.06 % |
Genmab (GMAB) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q1 | 2025-05-08 | $715.00M | $748.58M | -4.49 % |
| Q4 | 2025-02-12 | $921.56M | $885.31M | 4.09 % |
| Q3 | 2024-11-06 | $816.01M | $828.46M | -1.50 % |
| Q2 | 2024-08-08 | $779.51M | $733.18M | 6.32 % |
FAQ
When is Genmab (NASDAQ:GMAB) reporting earnings?
Genmab (GMAB) is scheduled to report earnings on August 7, 2025. The last reported earnings were for reported on May 8, 2025 for Q1.
What were the latest earnings per share (EPS) for Genmab (NASDAQ:GMAB)?
The Actual EPS was $0.31, which beat the estimate of $0.23.
What were Genmab’s (NASDAQ:GMAB) revenues?
The Actual Revenue was $715M, which missed the estimate of $748.6M.
Browse earnings estimates, EPS, and revenue on all stocks.
